Skip Navigation

European Journal of Heart Failure 2001 3(6):637-639; doi:10.1016/S1388-9842(01)00211-2
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2001 European Society of Cardiology

ACE Inhibitors for ‘Diastolic’ Heart Failure? Reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure

Prof. John G.F. Cleland

University of Hull, Castle Hill Hospital, Department of Cardiology Castle Rd. Cottingham, Kingston upon Hull HU16 5JQ, UK.

The first 10% of the full text of this article appears below.

Guidelines for the management of heart failure highlight the importance of ACE inhibitors for the management of patients with left ventricular systolic dysfunction [1]. However, guidelines make no recommendation for their use in patients with heart failure and preserved left ventricular systolic function. The pathophysiology and diagnosis of ‘diastolic’ heart failure is complex. There are sound theoretical reasons why ACE inhibitors might improve symptoms and prognosis in this setting but little evidence.

The entry criteria for the V-HeFT . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
Task Force Members, J. Lopez-Sendon, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al.
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: The Task Force on ACE-inhibitors of the European Society of Cardiology
Eur. Heart J., August 2, 2004; 25(16): 1454 - 1470.
[Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. Metra, S. Nodari, and L. Dei Cas
Current guidelines in the pharmacological management of chronic heart failure
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1_suppl): S11 - S16.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
J. B. Braunstein, G. F. Anderson, G. Gerstenblith, W. Weller, M. Niefeld, R. Herbert, and A. W. Wu
Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure
J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1226 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. Nodari, M. Metra, and L. D. Cas
{beta}-Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol
Eur J Heart Fail, October 1, 2003; 5(5): 621 - 627.
[Abstract] [Full Text] [PDF]